SpringerLink
Log in

Vasopressin Receptor Antagonists

  • Chapter
  • First Online:
Hyponatremia

  • 2457 Accesses

Abstract

Arginine vasopressin is the hormone principally responsible for the genesis of most hyponatremic disorders. The persistent inappropriate or maladaptive secretion of this hormone, also known as antidiuretic hormone, prevents excretion of electrolyte-free water leading to water retention and hyponatremia. The vasopressin receptor antagonists, or “vaptans,” are a promising new alternative to the often impractical or ineffective conventional therapies used in many hyponatremic patients currently. The development of vaptans is the culmination of efforts which began more than a century ago. After briefly discussing the vital milestones in the work that led to the introduction of vaptans, this chapter will focus on the major studies that established the specificity, efficacy, and safety of vaptans in the treatment of euvolemic and hypervolemic hyponatremia. We will also review the studies that have shown that the vaptans are not helpful for the primary treatment of chronic heart failure and cirrhosis independent of hyponatremia. Finally, we will discuss the indications and proper use of this new class of drugs, as well as the current impediments to their use and the areas in which further study is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now
Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 93.08
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 117.69
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 160.49
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001;51(3):372–90.

    Article  PubMed  CAS  Google Scholar 

  2. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000;11(10):406–10.

    Article  PubMed  CAS  Google Scholar 

  3. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–32.

    Article  PubMed  CAS  Google Scholar 

  4. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1–receptor physiology. Crit Care. 2003;7(6):427–34.

    Article  PubMed  Google Scholar 

  5. Laszlo FA, Laszlo Jr F, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991;43(1):73–108.

    PubMed  CAS  Google Scholar 

  6. Kinter LB, Huffman WF, Stassen FL. Antagonists of the antidiuretic activity of vasopressin. Am J Physiol. 1988;254(2 Pt 2):F165–77.

    PubMed  CAS  Google Scholar 

  7. Manning M, Lammek B, Kolodziejczyk AM, Seto J, Sawyer WH. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin. J Med Chem. 1981;24(6):701–6.

    Article  PubMed  CAS  Google Scholar 

  8. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  9. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992;105(4):787–91.

    Article  PubMed  CAS  Google Scholar 

  10. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Map** the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther. 2006;316(2):564–71.

    Article  PubMed  CAS  Google Scholar 

  11. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest. 1993;92(6):2653–9.

    Article  PubMed  CAS  Google Scholar 

  12. Yamaguchi K, Shijubo N, Kodama T, et al. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011;41(1):148–52.

    Article  PubMed  Google Scholar 

  13. Serradeil-Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest. 1996;98(12):2729–38.

    Article  PubMed  CAS  Google Scholar 

  14. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1(6):1154–60.

    Article  PubMed  CAS  Google Scholar 

  15. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37(1):182–91.

    Article  PubMed  CAS  Google Scholar 

  16. Abraham WT, Decaux G, Josiassen R, et al. Safety and efficacy of the vasopressin-2 receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia. Paper presented at: American Society of Nephrology Annual Meeting 2011; Philadelphia.

    Google Scholar 

  17. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110(7):582–4.

    Article  PubMed  CAS  Google Scholar 

  18. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–52.

    Article  PubMed  CAS  Google Scholar 

  19. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337(1):28–36.

    Article  PubMed  Google Scholar 

  20. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57.

    Article  PubMed  CAS  Google Scholar 

  21. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287(3):860–7.

    PubMed  CAS  Google Scholar 

  22. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol. 2007;47(12):1498–507.

    Article  PubMed  CAS  Google Scholar 

  23. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112.

    Article  PubMed  CAS  Google Scholar 

  24. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–12.

    Article  PubMed  CAS  Google Scholar 

  25. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69(12):2124–30.

    Article  PubMed  CAS  Google Scholar 

  26. Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists? J Am Soc Nephrol. 2008;19(6):1054–8.

    Article  PubMed  CAS  Google Scholar 

  27. Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol. 2010;21(4):552–5.

    Article  PubMed  CAS  Google Scholar 

  28. Murry L (ed). Red Book® 2010: Pharmacy’s Fundamental Reference. 114 Edition. Montvale, NJ: PDR Network, 2010.

    Google Scholar 

  29. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006;4:10.

    Article  PubMed  Google Scholar 

  30. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol. 2008;19(4):764–70.

    Article  PubMed  CAS  Google Scholar 

  31. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984;101(3):370–7.

    Article  PubMed  CAS  Google Scholar 

  32. Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73 Suppl 3:S19–23.

    Article  PubMed  Google Scholar 

  33. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305(5):263–6.

    Article  PubMed  CAS  Google Scholar 

  34. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82(5):1724–9.

    Article  PubMed  CAS  Google Scholar 

  35. Stone CK, Liang CS, Imai N, Sakamoto S, Sladek CD, Hood Jr WB. Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. Circulation. 1988;78(5 Pt 1):1251–9.

    Article  PubMed  CAS  Google Scholar 

  36. Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J Clin Invest. 1986;78(3):674–9.

    Article  PubMed  CAS  Google Scholar 

  37. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267(6 Pt 2):H2245–54.

    PubMed  CAS  Google Scholar 

  38. Mulinari RA, Gavras I, Wang YX, Franco R, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation. 1990;81(1):308–11.

    Article  PubMed  CAS  Google Scholar 

  39. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104(20):2417–23.

    Article  PubMed  CAS  Google Scholar 

  40. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47(8):1615–21.

    Article  PubMed  CAS  Google Scholar 

  41. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690–6.

    Article  PubMed  CAS  Google Scholar 

  42. Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.

    Article  PubMed  CAS  Google Scholar 

  43. Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319–31.

    Article  PubMed  CAS  Google Scholar 

  44. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.

    Article  PubMed  CAS  Google Scholar 

  45. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol. 2005;39(4 Suppl 2):S131–7.

    Article  PubMed  CAS  Google Scholar 

  46. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151–7.

    Article  PubMed  CAS  Google Scholar 

  47. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982;96(4):413–7.

    Article  PubMed  CAS  Google Scholar 

  48. Claria J, Jimenez W, Arroyo V, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 1989;97(5):1294–9.

    PubMed  CAS  Google Scholar 

  49. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994;46(1):237–44.

    Article  PubMed  CAS  Google Scholar 

  50. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124(4):933–9.

    Article  PubMed  CAS  Google Scholar 

  51. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48(1):204–13.

    Article  PubMed  CAS  Google Scholar 

  52. Cardenas A, Gines P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571–8.

    Article  PubMed  CAS  Google Scholar 

  53. Krag A, Moller S, Pedersen EB, Henriksen JH, Holstein-Rathlou NH, Bendtsen F. Impaired free water excretion in child C cirrhosis and ascites: relations to distal tubular function and the vasopressin system. Liver Int. 2010;30(9):1364–70.

    Article  PubMed  CAS  Google Scholar 

  54. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53(2):283–90.

    Article  PubMed  CAS  Google Scholar 

  55. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45(9):979–87.

    Article  PubMed  CAS  Google Scholar 

  56. Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61(1):108–16.

    Article  PubMed  CAS  Google Scholar 

  57. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–71.

    Article  PubMed  CAS  Google Scholar 

  58. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97(7):1064–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC, USA

    Mehul B. Patel M.D., Ruediger W. Lehrich M.D. & Arthur Greenberg M.D.

Authors
  1. Mehul B. Patel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruediger W. Lehrich M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arthur Greenberg M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arthur Greenberg M.D. .

Editor information

Editors and Affiliations

  1. Section of Nephrology and Hypertension, Tulane University Health Sciences Center, Tulane Ave 1430, New Orleans, 70112, Louisiana, USA

    Eric E. Simon

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Patel, M.B., Lehrich, R.W., Greenberg, A. (2013). Vasopressin Receptor Antagonists. In: Simon, E. (eds) Hyponatremia. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6645-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6645-1_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6644-4

  • Online ISBN: 978-1-4614-6645-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation